As part of the Internationalisation activities and of the Zhongguancun Enterprise Service Representative Office in Italy, the Italian Office of Beijing's Zhongguancun District, SPICI promotes and coordinates Italian participation in the P4 Global-to-China Precision Medicine Acceleration Program 2026, an international acceleration programme dedicated to businesses and research groups active in the fields of life sciences, precision medicine, biopharmaceuticals, medical technologies, artificial intelligence applied to healthcare, and advanced biomedical technologies.

The programme will take place in China from 21 June to 1 July 2026, with stops in Beijing (the capital) and Hainan (“the Chinese Hawaii”), and will offer selected teams a structured pathway to access the Chinese precision medicine ecosystem through clinical validation activities, industrial matchmaking, meetings with hospitals, investors, and institutional partners, mentoring sessions, and investment opportunities.

Participation in the programme is free of charge, and travel and accommodation expenses will be covered for the selected teams.

The P4 Global-to-China Precision Medicine Acceleration Program 2026

The P4 Global-to-China Precision Medicine Acceleration Program 2026 is an international acceleration programme promoted by the P4 Precision Medicine Innovation Centre Beijing, the Chinese hub of the London-based P4 Precision Medicine Accelerator, established thanks to a collaboration between the P4 Accelerator of London, the UK Government, the China Investment Promotion Agency, ITTN – International Technology Transfer Network, and the Peking University Third Hospital.

The programme was created with the aim of supporting healthcare companies and research groups in entering, clinically validating, and commercially developing within the Chinese market, fostering connections between startups, innovative enterprises, spin-offs, research centres, and China's healthcare, industrial, and financial ecosystem.

Why participate

China is currently one of the most dynamic markets in the world for the development of precision medicine, biopharmaceuticals, medical devices, advanced diagnostics, and artificial intelligence applied to healthcare.

The programme offers participants qualified access to:

·       Chinese hospital networks and clinical institutions;

·       industrial partners and companies in the healthcare and life science sectors;

·       investors, healthcare funds, and corporate innovation units;

·       clinical validation and Proof of Concept pathways;

·       opportunities for localisation, technology transfer, and entry into the Chinese market;

·       policy and regulatory guidance tools;

·       innovation programmes, roadshows, and matchmaking activities in China.

For Italian SMEs, startups, university spin-offs, and research groups, the initiative represents a concrete opportunity to test the potential of their technology in an international ecosystem with a high demand for innovation, build relationships with clinical and industrial partners, and evaluate commercial development pathways in China.

Target audience and technological areas

The call is addressed to:

· SMEs;
· startups;
· university spin-offs;
· research groups.

Opportunities for the selected teams

With the support of P4 and SPICI, which manages the Zhongguancun Enterprise Service Representative Office in Italy, the selected teams will be able to access a structured acceleration pathway, which includes:

·       B2B/B2G matchmaking with hospitals, clinical institutions, industrial partners, companies, government bodies, and investors;

·       support on entering the Chinese market, regulatory processes, clinical validation, and Proof of Concept;

·       mentoring sessions with experts in the healthcare, life science, and precision medicine sectors;

·       pitch sessions and project presentations to industrial partners and investors;

·       collaboration opportunities with Chinese clinical institutions and industrial entities;

·       access to SAFE investment opportunities;

·       coverage of travel and accommodation expenses for the selected teams.

Programme stages

The journey will take place across China's main healthcare and biomedical innovation hubs:

Beijing | 21 – 26 June 2026

First phase of the programme, dedicated to acceleration activities, mentoring sessions, project roadshows, B2B/B2G meetings, and matchmaking with hospitals, industrial partners, institutions, and investors.

Hainan | 27 June – 1 July 2026

Second phase of the programme, dedicated to acceleration and networking activities, meetings with the local ecosystem, project presentations, matchmaking, and in-depth insights into development opportunities in the healthcare and life science sectors in China.

How to apply and deadlines

Participation is free of charge. Applications must be submitted via Google Form: https://forms.gle/nhPte7xSkjpVC4ex5 by 4 June 2026. After completing the form, you must send an email to startup@spici.eu, attaching:

·       pitch deck in English;

·       copy of the company representative's passport.

Email subject line: “P4 Precision Medicine Accelerator 2026, Name of Company/Entity, Expression of Interest”

Applications will be evaluated by the Programme organisers.

FOCUS: Beijing, the Zhongguancun District, and the Italian Office managed by SPICI

Beijing is one of the world's leading hubs for innovation, scientific research, the digital economy, and technological development. With a GDP of nearly $700 billion, the Chinese capital ranks among the country's top economies and represents a strategic market for companies, startups, and research centres interested in developing technological partnerships, accessing investors, industrial collaborations, and soft-landing pathways in China.

The heart of Beijing’s innovation ecosystem is the Zhongguancun District, recognised as one of China's most important high-tech districts and often referred to as the “Chinese Silicon Valley”.  The area is developed in close proximity to some of the country's leading academic and scientific institutions, including Tsinghua University, Peking University, Beijing Normal University, and the Chinese Academy of Sciences, and is historically linked to the birth and growth of major Chinese and international technology players.

The District is home to some of China's largest tech companies, including Baidu, Lenovo, Xiaomi, TikTok, and Kingsoft,  as well as deep-tech and AI companies such as DeepSeek, Moonshot AI, Horizon Robotics, and Cambricon. The area also hosts the regional hubs and R&D centres of numerous international players, including Microsoft, Google, Intel, AMD, IBM, Oracle, Sony, Apple, NVIDIA, TSMC, Samsung, Texas Instruments, HP, Dell, Red Hat, ARM, ASML, and GlobalFoundries.

In this context, since 2025 SPICI has been managing the Zhongguancun Enterprise Service Representative Office in Italy, the Italian Office of the Zhongguancun District, which acts as an operational bridge between the Italian ecosystem and the city of Beijing. The Office facilitates scouting, guidance, applications to international programmes and awards, B2B/B2G matchmaking, soft landing, and entry into the respective markets.